Radiopharm Theranostics (ASX:RAD) secured regulatory approval to expand its phase 1 trial investigating the safety and tolerability of 177Lu-RAD204, a treatment candidate for non-small cell lung cancer, according to a Tuesday filing with the Australian bourse.

Specifically, the Australian Human Research Ethics Committee cleared the trial to include five other forms of cancer with programmed death-ligand 1 (PD-L1) expressing solid tumors, such as PD-L1 positive small cell lung cancer, triple-negative breast cancer, melanoma, head and neck cancer, and endometrial cancer, the filing said.

The trial is currently underway at four sites across Australia, as per the filing.

Radiopharm Theranostics' shares were up almost 4% in recent Tuesday trade.

Price (AUD): $0.03, Change: $+0.001, Percent Change: +3.84%